MARKET

QURE

QURE

Uniqure
NASDAQ
4.780
-0.250
-4.97%
After Hours: 4.850 +0.07 +1.46% 17:14 04/12 EDT
OPEN
4.960
PREV CLOSE
5.03
HIGH
5.03
LOW
4.720
VOLUME
1.22M
TURNOVER
0
52 WEEK HIGH
22.48
52 WEEK LOW
4.720
MARKET CAP
228.67M
P/E (TTM)
-0.7387
1D
5D
1M
3M
1Y
5Y
Analysts Offer Insights on Healthcare Companies: Marinus (MRNS), uniQure (QURE) and eFFECTOR Therapeutics (EFTR)
TipRanks · 3d ago
Weekly Report: what happened at QURE last week (0401-0405)?
Weekly Report · 4d ago
UNIQURE NV <QURE.O>: UBS CUTS TARGET PRICE TO $27 FROM $38
Reuters · 04/02 13:45
Weekly Report: what happened at QURE last week (0325-0329)?
Weekly Report · 04/01 09:10
Weekly Report: what happened at QURE last week (0318-0322)?
Weekly Report · 03/25 09:10
Weekly Report: what happened at QURE last week (0311-0315)?
Weekly Report · 03/18 09:10
Weekly Report: what happened at QURE last week (0304-0308)?
Weekly Report · 03/11 09:10
AMD To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Monday
B of A Securities boosted the price target for Li Auto Inc. (NASDAQ:LI) to $60. Barclays increased Advanced Micro Devices, Inc. Price target from $200 to $235 on Friday. TD Cowen maintained an Outperform rating for MasTec. Needham increased the price targets for HashiCorp and Dollar Tree.
Benzinga · 03/04 12:56
More
About QURE
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.

Webull offers Uniqure NV stock information, including NASDAQ: QURE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, QURE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading QURE stock methods without spending real money on the virtual paper trading platform.